BioLineRx Reports First Quarter 2016 Financial Results

Go back to BioLineRx Reports First Quarter 2016 Financial Results

Roth Affirms BioLineRx (BLRX( at 'Buy'; Balance Sheet Strong as BL-8040 Momentum Builds

May 17, 2016 2:15 PM UTC

Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q1 results reported earlier. BLRX reported Q1 EPS of ($0.10), which was $0.02 worse than the analyst estimate of ($0.08).

Analyst Joseph Pantginis commented, BL-8040 continues to be the lead value driver with initial positive data in r/rAML, an ongoing Phase II in consolidation AML and positive stem cell... More